On A Roll, AstraZeneca Aims For ‘Industry-Leading’ Growth From 2025
Second Antibody Drug Conjugate Is Next Milestone
AstraZeneca’s momentum is growing towards ‘industry-leading' revenue growth, but investors are focused on the operating margin, and concerned about when CEO Pascal Soriot will depart.
